tiprankstipranks
Trending News
More News >
Microbix Biosystms J (TSE:MBX)
TSX:MBX
Canadian Market

Microbix Biosystms (MBX) AI Stock Analysis

Compare
35 Followers

Top Page

TS

Microbix Biosystms

(TSX:MBX)

Rating:68Neutral
Price Target:
C$0.50
▲(66.67%Upside)
Microbix Biosystems exhibits strong financial performance and strategic advancements, particularly noted in the recent earnings call and corporate events. However, technical indicators suggest potential short-term price weakness, and valuation metrics indicate moderate appeal. The company's proactive measures and partnerships position it well for future growth despite industry challenges.
Positive Factors
Financial Performance
Antigen revenues beat this quarter, increasing 5% year-over-year to $4.3 million.
Market Expansion
With increased adoption in emerging markets and expansion into recombinant antigens, continued robust growth of this product line is expected.
Trade Benefits
Microbix products are currently exempt from tariffs under the USMCA trade agreement, allowing sales into the U.S. without additional costs.
Negative Factors
Demand Reduction
The unusually light burden of respiratory infectious diseases in China has decreased the demand for Microbix's antigen shipments.
Revenue Decline
Total revenues declined 28% year-over-year.
Sales Decline
Sales of antigens for Chinese customers have abruptly stopped, impacting a significant portion of the company's revenue.

Microbix Biosystms (MBX) vs. iShares MSCI Canada ETF (EWC)

Microbix Biosystms Business Overview & Revenue Model

Company DescriptionMicrobix Biosystems Inc. (MBX) is a biotechnology company headquartered in Canada that specializes in the development and commercialization of biological products and technologies. The company operates in the life sciences sector and focuses on three main areas: the manufacture of viral and bacterial antigens for the diagnostics industry, the development of quality assessment products (QAPs) for infectious disease diagnostics, and the production of biologic solutions for research and development purposes.
How the Company Makes MoneyMicrobix Biosystems generates revenue primarily through the sale of its antigens and quality assessment products to diagnostic and pharmaceutical companies. These products are essential for various diagnostic tests, including those for infectious diseases, where they help ensure the accuracy and reliability of test results. Microbix also capitalizes on its proprietary technologies to produce specific biological solutions, which are sold to researchers and developers in the life sciences industry. The company may engage in partnerships or collaborations with other biotechnology and pharmaceutical companies to expand its reach and product offerings, contributing to its revenue streams.

Microbix Biosystms Earnings Call Summary

Earnings Call Date:May 15, 2025
(Q2-2025)
|
% Change Since: -16.67%|
Next Earnings Date:Aug 13, 2025
Earnings Call Sentiment Positive
The earnings call highlighted strong financial performance, increased margins, and successful operational advancements. However, challenges such as anticipated weaker sales in the second half and delays with a QAPs partner were noted. Despite these challenges, the company's strategic initiatives and financial strength position it well for future growth.
Q2-2025 Updates
Positive Updates
Increased Revenue and Strong Margins
Q2 revenue reached $5.3 million with a 60% gross margin, up 7% from the previous year. For the first half, revenue was $11.4 million, with gross margins up by 10% year-over-year.
Operational and Financial Strength
The company exercised $2.7 million in warrants and options, paid down $1.15 million in mortgage, and doubled the credit line from $2 million to $4 million. Current ratio is at 9.36 and debt-to-equity ratio at 0.27.
Advancement in Recombinant Capabilities
Microbix has commissioned recombinant capabilities, opening substantial new markets for test ingredients and broadening the company's service offerings.
Global Leadership in HPV Screening
Progress in the QAPs business with leadership in screening for human papillomavirus and enabling global transition to molecular diagnostics.
Strong Partnerships and Program Milestones
Partnership with Sequel Pharma for the Kinylytic urokinase program and a major milestone achieved on May 5th, indicating the program is progressing well.
Operational Efficiency Gains
Manufacturing process upgrades have improved margins, reduced scrap rates, and enhanced yields, supported by digitization and automation.
Negative Updates
Challenging Outlook for Second Half
Weaker sales of test ingredients forecasted for the second half, particularly due to reduced respiratory antigen sales in China.
Delay in QAPs Partner Development
One major QAPs customer shifted from parallel to serial development, impacting short-term revenue expectations.
Company Guidance
In the recent call discussing Microbix's Q2 2025 results, the company reported solid financial performance with total revenues of $5.3 million for the quarter and $11.4 million for the first half of the fiscal year. Gross margins improved significantly, reaching 60% in Q2, up 7% from the previous year. Net earnings for the first half stood at $900,000. Operationally, Microbix expanded its capabilities with recombinant antigen technology and made strides in the QAPs business, despite anticipating a more challenging second half due to a slowdown in sales to China. The balance sheet was strengthened, with a current ratio of 9.36 and a debt-to-equity ratio of 0.27. Additionally, the company exercised $2.7 million in warrants and options, enhancing its financial position. The company also highlighted progress in its therapeutic drug asset, Kinlytic urokinase, which is advancing well with its partner Sequel Pharma.

Microbix Biosystms Financial Statement Overview

Summary
Microbix Biosystems demonstrates strong revenue growth and improved profitability margins with a stable balance sheet and positive cash flows. However, the potential challenges in maintaining revenue momentum and capital intensity in the biotechnology industry require careful management.
Income Statement
75
Positive
Microbix Biosystems has shown strong revenue growth from 2020 to 2024, with a significant improvement in net profit margins. The company achieved a positive net income in recent years, contrasting with previous losses. Notably, the TTM (Trailing-Twelve-Months) data indicates a gross profit margin of 56.1% and a net profit margin of 8.3%, pointing to improved profitability. However, the recent decline in total revenue from the annual report suggests potential challenges in maintaining revenue momentum.
Balance Sheet
70
Positive
The company's balance sheet reflects a stable equity base, with a notable decrease in debt levels over the years. The debt-to-equity ratio shows a moderate level of leverage, which is manageable. The equity ratio has been improving, indicating a stronger financial position. However, the biotechnology industry is capital intensive, and continuous investment might affect leverage ratios.
Cash Flow
65
Positive
Microbix Biosystems has demonstrated an improvement in operating cash flow, achieving positive free cash flow in the latest periods. The free cash flow to net income ratio suggests healthy cash generation relative to profits. However, past periods of negative free cash flow highlight potential liquidity risks if revenue declines or investment increases unexpectedly.
Breakdown
TTMSep 2024Sep 2023Sep 2022Sep 2021Sep 2020
Income StatementTotal Revenue
23.03M25.39M16.51M19.08M18.59M10.52M
Gross Profit
12.92M15.39M7.48M11.12M11.04M4.66M
EBIT
1.59M3.91M-2.74M2.69M4.84M-524.60K
EBITDA
4.51M6.21M1.96M3.73M5.66M-2.91M
Net Income Common Stockholders
1.92M3.52M-39.48K1.79M1.63M-6.23M
Balance SheetCash, Cash Equivalents and Short-Term Investments
13.05M12.96M11.61M13.49M9.99M92.66K
Total Assets
39.30M38.10M35.65M33.15M28.83M15.60M
Total Debt
6.44M6.40M6.65M5.82M7.74M6.17M
Net Debt
-6.61M-6.57M-4.96M-7.66M-2.25M6.08M
Total Liabilities
10.40M9.80M11.03M8.21M10.27M8.98M
Stockholders Equity
28.90M28.30M24.62M24.94M18.56M6.62M
Cash FlowFree Cash Flow
1.73M2.44M-2.11M1.44M804.20K-805.34K
Operating Cash Flow
3.80M4.35M-1.09M3.47M2.11M8.57K
Investing Cash Flow
-2.07M-1.91M-1.02M-2.03M-622.34K-813.91K
Financing Cash Flow
-1.46M-1.08M229.21K2.06M8.41M802.43K

Microbix Biosystms Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.30
Price Trends
50DMA
0.36
Negative
100DMA
0.40
Negative
200DMA
0.38
Negative
Market Momentum
MACD
-0.01
Positive
RSI
33.62
Neutral
STOCH
6.06
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MBX, the sentiment is Negative. The current price of 0.3 is below the 20-day moving average (MA) of 0.34, below the 50-day MA of 0.36, and below the 200-day MA of 0.38, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 33.62 is Neutral, neither overbought nor oversold. The STOCH value of 6.06 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MBX.

Microbix Biosystms Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
TSCOV
77
Outperform
C$64.43M16.8414.51%28.97%
TSMBX
68
Neutral
C$42.94M26.295.32%-4.67%-60.94%
54
Neutral
$5.31B3.29-45.39%2.79%16.77%-0.07%
TSMIR
46
Neutral
C$60.66M
-32.14%-52.38%
TSONC
43
Neutral
$39.97M-211.24%0.10%
TSSVA
33
Underperform
C$54.20M248.46%32.71%
TSHBP
33
Underperform
C$68.22M685.26%-50.29%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:MBX
Microbix Biosystms
0.30
-0.04
-11.76%
TSE:ONC
Oncolytics Biotech
0.49
-0.93
-65.49%
TSE:HBP
Helix BioPharma
0.92
-0.16
-14.81%
TSE:MIR
Medmira
0.08
0.00
0.00%
TSE:COV
Covalon Technologies
2.37
0.37
18.50%
TSE:SVA
Sernova
0.17
-0.13
-43.33%

Microbix Biosystms Corporate Events

Business Operations and StrategyFinancial Disclosures
Microbix Biosystems Reports Q2 Fiscal 2025 Results with Improved Margins and Cautious Outlook
Neutral
May 15, 2025

Microbix Biosystems reported its Q2 fiscal 2025 results, showing a revenue of $5.3 million, a slight decrease from the previous year, but with improved gross margins. The company experienced growth in antigen sales, offset by a decline in QAPs due to delays with a major customer. Despite increased operating expenses, Microbix achieved a positive net income and improved financial strength, with strong cash reserves and liquidity. However, the outlook for the second half of fiscal 2025 is cautious due to reduced sales in China, impacting the company’s future growth prospects.

The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.80 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
Microbix and Aurevia Launch Pilot EQA Program for Bacterial Vaginosis Diagnosis
Positive
May 13, 2025

Microbix Biosystems Inc., in collaboration with Aurevia Oy, has launched a pilot external quality assessment (EQA) program aimed at enhancing the proficiency of clinical laboratories in diagnosing bacterial vaginosis (BV) using molecular diagnostic methods. This initiative, which involves the use of Microbix’s QAPs to simulate clinical specimens, is expected to improve diagnostic accuracy and treatment planning for BV and other vaginal infections. The program’s success could lead to its inclusion in Aurevia’s Labquality EQAS portfolio, thereby strengthening Microbix’s position as a key partner in the diagnostics industry.

The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.80 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Financial Disclosures
Microbix Biosystems to Release Q2 Fiscal 2025 Results
Neutral
May 8, 2025

Microbix Biosystems Inc. has announced the release of its second quarter fiscal 2025 financial results, scheduled for May 15, 2025. The company will host a webinar to discuss these results, featuring its CEO, CFO, and COO. This event reflects Microbix’s ongoing commitment to transparency and engagement with investors and stakeholders, potentially impacting its market positioning and investor relations.

Product-Related AnnouncementsBusiness Operations and Strategy
Microbix Advances Kinlytic Urokinase Production with New CDMO Agreement
Positive
May 5, 2025

Microbix Biosystems Inc. announced that its partner, Sequel Pharma, has signed an agreement with a contract development and manufacturing organization (CDMO) to produce Kinlytic® urokinase, a drug for dissolving blood clots. This agreement aims to resume production for the U.S. market, initially targeting the catheter clearance segment valued at $400 million. The collaboration is expected to enhance Microbix’s market presence and operational capabilities, with future updates anticipated as the project progresses.

Business Operations and Strategy
Microbix to Present at 2025 Bloom Burton Healthcare Investor Conference
Neutral
May 1, 2025

Microbix Biosystems Inc. announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference, which will be held at the Metro Toronto Convention Centre. This event provides Microbix with a platform to connect with Canadian, U.S., and international investors, potentially enhancing its market presence and stakeholder engagement in the healthcare and life sciences sector.

Product-Related AnnouncementsBusiness Operations and Strategy
Microbix to Showcase Diagnostic Innovations at ESCMID Global 2025
Positive
Apr 9, 2025

Microbix Biosystems Inc. announced its participation in the ESCMID Global 2025 conference, where it will showcase its innovative Quality Assessment Products (QAPs) designed to ensure the accuracy of diagnostic tests. A customer and collaborator, Labquality EQAS by Aurevia, will present results from a pilot External Quality Assessment program for Norovirus antigen detection, supported by Microbix’s QAPs. This initiative highlights Microbix’s capability to create effective controls for challenging antigen materials, enhancing its industry positioning and demonstrating its commitment to quality management in diagnostics.

Business Operations and StrategyFinancial Disclosures
Microbix Biosystems Navigates Tariff Challenges with Strategic Growth
Neutral
Apr 8, 2025

Microbix Biosystems Inc. announced that its products remain exempt from new U.S. tariffs, providing a competitive edge over other international exporters facing tariffs. The company is also exploring Canadian procurement opportunities amid potential reciprocal tariffs on U.S. goods. While the outlook for its QAPs business remains strong, sales of test-ingredients, particularly antigens, have been affected by reduced demand in China. Despite these challenges, Microbix continues to expand its capabilities and remains financially robust, with significant cash reserves and ongoing strategic initiatives in diagnostics and synthetic biology.

Shareholder MeetingsBusiness Operations and Strategy
Microbix Biosystems Announces Successful Shareholder Meeting Outcomes
Positive
Mar 27, 2025

Microbix Biosystems Inc. announced the results of its Annual and Special Meeting of Shareholders, where 42.83% of the issued and outstanding shares were represented, and all resolutions were approved, including the re-election of board members and the re-appointment of auditors. This positive outcome reflects shareholder confidence and supports the company’s ongoing operations and strategic initiatives in the life sciences sector.

Private Placements and FinancingBusiness Operations and Strategy
Microbix Optimizes Capital Structure for Greater Financial Flexibility
Positive
Mar 26, 2025

Microbix Biosystems Inc. has optimized its capital structure by repaying a C$ 1.2 million mortgage and expanding its line of credit from C$ 2.0 million to C$ 4.0 million. These financial moves are expected to reduce interest expenses and provide greater strategic flexibility, allowing the company to reinvest in growth and adapt to market changes. With these changes, Microbix aims to maintain financial strength, support operations, and ensure resilience against economic uncertainties.

Business Operations and Strategy
Microbix Partners with ACPCC to Combat Cervical Cancer in Indo-Pacific
Positive
Mar 17, 2025

Microbix Biosystems Inc. has signed a Memorandum of Understanding with the Australian Centre for the Prevention of Cervical Cancer (ACPCC) to supply its PROCEEDxFLOQ brand Quality Assessment Products (QAPs) to support the accuracy of HPV testing in the Indo-Pacific region. This collaboration is part of the EPICC program, which aims to eliminate cervical cancer in the region by improving the prevention, diagnosis, and treatment of the disease. The initiative is supported by the Australian Government and philanthropic partners and seeks to extend its proven model to additional countries, enhancing access to accurate HPV testing and reducing the human toll of cervical cancer.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.